Author

Romain Fernandes

Centre National de la Recherche Scientifique

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:metabolomics· 2 Research Focus:drug response / drug discovery· 1 Research Focus:metabolism & bioenergetics· 1 Assay:proteomics· 1

Frequent Co-Authors

Antonin MarchaisiD· 2 shared Birgit GeoergeriD· 2 shared Catherine BrenneriD· 2 shared Daniela Dias‐PedrosoiD· 2 shared Guido KroemeriD· 2 shared Hong-Toan LaiiD· 2 shared Liuba MazzantiiD· 2 shared Maria Eugénia Marques Da CostaiD· 2 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

Antonin MarchaisORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Engineered flavonoid disrupts mitochondrial AIF/CHCHD4 complex for targeted cancer therapy

Hong-Toan Lai, Daniela Dias‐Pedroso, Maria Eugénia Marques Da Costa, Romain Fernandes, Tran Ngoc Anh Nguyen, Olivia Bawa, Pierre Khneisser, João Gabriel Silva, Yassine Khalij, Michelangelo Campanella, John Griffith Jones, Svetlana Dokudovskaya, Guido Kroemer, Antonin Marchais, Nathalie Gaspar, , Catherine Brenner

This paper identifies M30-E05, an engineered flavonoid that disrupts the AIF/CHCHD4 mitochondrial complex, reducing cancer cell viability and tumor growth in xenograft models.

Acta Pharmaceutica Sinica B · Jun 15, 2026Peer-reviewedPharmacology & Toxicology

Combined inhibition of AIF/CHCHD4 interaction and GLS1 to exploit metabolic vulnerabilities in pediatric osteosarcoma

Hong-Toan Lai, Tran Ngoc Anh Nguyen, Maria Eugénia Marques Da Costa, Romain Fernandes, Daniela Dias‐Pedroso, Sylvère Durand, Guido Kroemer, Reynand Jay Canoy, Liuba Mazzanti, Yegor S Vassetzky, Nathalie Gaspar, Antonin Marchais, Birgit Geoerger, Tâp Ha‐Duong, Catherine Brenner

This study identifies a metabolic vulnerability in osteosarcoma by combining AIF/CHCHD4 inhibition and GLS1 suppression, showing synergy between mitoxantrone and telaglenastat in vitro and in vivo.

bioRxiv · Apr 7, 2026 · PreprintCancer Biology